| Cell line name |
OV-MZ-32 |
| Synonyms |
OVMZ32; OVarian-MainZ-32 |
| Accession |
CVCL_X956 |
| Resource Identification Initiative |
To cite this cell line use: OV-MZ-32 (RRID:CVCL_X956) |
| Comments |
Derived from site: Metastatic; Omentum; UBERON=UBERON_0003688. |
| Disease |
Ovarian serous cystadenocarcinoma (NCIt: C7978) |
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
| Sex of cell |
Female |
| Age at sampling |
44Y |
| Category |
Cancer cell line |
| Publications | PubMed=10741907; DOI=10.1007/s004320050023 Qi Wu, Rolf Kreienberg, Ingo Bernard Runnebaum; Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro. J. Cancer Res. Clin. Oncol. 126:139-144(2000) PubMed=11242531; DOI=10.1089/10430340150504019 Ansgar Bruning, Tanja Kohler, Sven Roy Quist, Shan Wang-Gohrke, Volker Jochen Mobus, Rolf Kreienberg, Ingo Bernard Runnebaum; Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphaVbeta3. Hum. Gene Ther. 12:391-399(2001) PubMed=11925137; DOI=10.1006/gyno.2002.6597 Matthias Oppitz, Volker Jochen Mobus, S. Brock, Ulrich Drews; Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients. Gynecol. Oncol. 85:159-164(2002) PubMed=15153938; DOI=10.1038/sj.cgt.7700727 Sven Roy Quist, Shan Wang-Gohrke, Tanja Kohler, Rolf Kreienberg, Ingo Bernard Runnebaum; Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther. 11:547-554(2004) |
| Cross-references |
| Encyclopedic resources |
Wikidata; Q54936859
|
| Entry history |
| Entry creation | 05-Sep-2014 |
| Last entry update | 27-Nov-2025 |
| Version number | 5 |
|---|